DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial-Reference-Cited by-同舟云学术

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial

Published:2018-11-02 Issue:11 Volume:13 Page:e0206837
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Houser Katherine V.,Yamshchikov Galina V.,Bellamy Abbie R.,May Jeanine,Enama Mary E.,Sarwar Uzma,Larkin Brenda,Bailer Robert T.,Koup Richard,Paskel Myeisha,Subbarao Kanta,Anderson Edwin,Bernstein David I.,Creech Buddy,Keyserling Harry,Spearman Paul^ORCID,Wright Peter F.,Graham Barney S.,Ledgerwood Julie E.^ORCID,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. The underrecognized burden of influenza in young children;KA Poehling;N Engl J Med,2006

2. Population-wide benefits of routine vaccination of children against influenza;D Weycker;Vaccine,2005

3. Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009–13;A Fowlkes;Lancet Respir Med,2015

4. Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza;S Cauchemez;Proc Natl Acad Sci U S A,2011

5. Influenza transmission in a cohort of households with children: 2010–2011;JG Petrie;PLoS One,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles;Cell;2024-09

2. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults;Science Translational Medicine;2023-04-19

3. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19);Archives of Microbiology;2023-03-30

4. Inactivated and Recombinant Influenza Vaccines;Plotkin's Vaccines;2023

5. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing;Expert Review of Vaccines;2022-06-09